Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation

  1. AJ Jääskeläinen
  2. S Kuivanen
  3. E Kekäläinen
  4. MJ Ahava
  5. R Loginov
  6. H Kallio-Kokko
  7. O Vapalahti
  8. H Jarva
  9. S Kurkela
  10. M Lappalainen

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.jcv.2020.104512
  2. ScreenIT

    SciScore for 10.1101/2020.05.18.20101618: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variableSerum samples comprising the negative panel: The negative panel consisted of 81 serum samples (from 81 individuals) (median age 64 years, range 2–89 years; 33 males, 31 females).
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Thirty-nine out of 81 samples contained autoantibodies: 21 had anti-nuclear antibodies in Hep-2 cell IFA analysis [NOVA Lite® DAPI ANA Kit, Inova Diagnostics, California, USA; staining patterns: homogenous, 7/21; speckled 7/21; centromere 4/21; centromere+anti-mitochondrial antibodies 1/21; nucleolar 1/21; speckled and nuclear dots 1/21], 10 were positive for phospholipase receptor A2 (PLA2R) antibodies (Anti-Phospholipase A2 Receptor IIFT (IgG) (Euroimmun, Lübeck, Germany), three for glomerular basement membrane (GBM) antibodies (EUROPLUS kidney (monkey) and GBM antigen IIFT, Euroimmun, Lübeck, Germany), and five for antineutrophil cytoplasmic (ANCA) antibodies (NOVA Lite® ANCA IFA Kit (Inova Diagnostics, California, USA) (Table 1).
    anti-nuclear
    suggested: None
    PLA2R
    suggested: None
    Anti-Phospholipase A2 Receptor IIFT ( IgG
    suggested: None
    antineutrophil cytoplasmic ( ANCA
    suggested: None
    Automated immunoassays for anti-SARS-CoV-2 IgG or IgA detection: The analysis of SARS-CoV-2 IgG or IgA antibodies were carried out using the Architect Plus i2000sr Analyzer (Abbott, Illinois, USA) and SARS-COV-2 IgG kit (nucleoprotein based antigen; Abbott; CE marked), EUROLabworkstation (Euroimmun, Lübeck, Germany) and SARS-CoV-2 IgG and IgA kits (S1-based antigen; Euroimmun) and Diasorin Liaison® XL (DiaSorin, Saluggia, Italy) and SARS-CoV-2 S1/S2 IgG kit (S1/S2 based antigen; DiaSorin; research use only) according to manufacturers´ instructions.
    anti-SARS-CoV-2 IgG
    suggested: None
    IgA
    suggested: (Lab Vision Cat# RM-9118-S1, RRID:AB_149966)
    DiaSorin, Saluggia, Italy
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Thirty-nine out of 81 samples contained autoantibodies: 21 had anti-nuclear antibodies in Hep-2 cell IFA analysis [NOVA Lite® DAPI ANA Kit, Inova Diagnostics, California, USA; staining patterns: homogenous, 7/21; speckled 7/21; centromere 4/21; centromere+anti-mitochondrial antibodies 1/21; nucleolar 1/21; speckled and nuclear dots 1/21], 10 were positive for phospholipase receptor A2 (PLA2R) antibodies (Anti-Phospholipase A2 Receptor IIFT (IgG) (Euroimmun, Lübeck, Germany), three for glomerular basement membrane (GBM) antibodies (EUROPLUS kidney (monkey) and GBM antigen IIFT, Euroimmun, Lübeck, Germany), and five for antineutrophil cytoplasmic (ANCA) antibodies (NOVA Lite® ANCA IFA Kit (Inova Diagnostics, California, USA) (Table 1).
    Hep-2
    suggested: None
    Briefly, Vero E6 cells (5⌎×⌎10^4/well) were plated on 96 w/p MEM supplemented with 10% of heat-inactivated FBS, glutamine, penicillin and streptomycin.
    Vero E6
    suggested: None
    Software and Algorithms
    SentencesResources
    Automated immunoassays for anti-SARS-CoV-2 IgG or IgA detection: The analysis of SARS-CoV-2 IgG or IgA antibodies were carried out using the Architect Plus i2000sr Analyzer (Abbott, Illinois, USA) and SARS-COV-2 IgG kit (nucleoprotein based antigen; Abbott; CE marked), EUROLabworkstation (Euroimmun, Lübeck, Germany) and SARS-CoV-2 IgG and IgA kits (S1-based antigen; Euroimmun) and Diasorin Liaison® XL (DiaSorin, Saluggia, Italy) and SARS-CoV-2 S1/S2 IgG kit (S1/S2 based antigen; DiaSorin; research use only) according to manufacturers´ instructions.
    Architect Plus
    suggested: None
    All samples from the negative panel (N=81) and the patient panel (N=70) were tested with Abbott SARS-CoV-2 IgG, and Euroimmun SARS-CoV-2 IgA and IgG.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.05.18.20101618v1 on medRxiv